Skip to main content


Melanoma

Study results show Medicare payment rates for Mohs micrographic surgery more than double those of other procedures for…
Immune checkpoint inhibitor therapy deliver in a real-world setting significantly improves survival in patients aged 65…
Clinical outcomes of melanoma patients who may benefit from combination immunotherapy can be predicted with circulating…
Adjuvant pembrolizumab was found to provide a “sustained and clinically meaningful” improvement in RFS at a median…
The national Melanoma Prevention Working Group identified limitations to implementing gene expression profile testing…
Nodal observation is the most cost-effective option for managing patients with sentinel lymph node-positive melanoma…
Adjuvant therapy with dabrafenib and trametinib extended duration of survival without relapse of distant metastasis…
Researchers identified sociodemographic factors associated with increased likelihood to receive immunotherapy for…
Study findings show the combination of ipilimumab and nivolumab is as effective in the real-world setting as it was in…
Pembrolizumab is associated with better real-world 24-week QoL compared to the combination of ipilimumab plus nivolumab…
Back to Top